SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement -
- Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative Breast, and Small Cell Lung Cancers and Acute Myeloid Leukemia -
- First Clinical Data Expected in First Quarter of 2020 -
NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the develop...